Therefore, dissecting these relevant clinical findings and understanding how other signaling pathways impinge on PI3K/Akt/mTOR signaling pathway activity may provide us new clues as to how to effectively inhibit this pathway with potential candidate combination strategies to eradicate LSCs and so cure AML. This evidence concerns the gene PIK3CA and acute myeloid leukemia.